127 related articles for article (PubMed ID: 25934177)
1. Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.
Schmieder RE; Gitt AK; Koch C; Bramlage P; Ouarrak T; Tschöpe D;
BMC Endocr Disord; 2015 May; 15():23. PubMed ID: 25934177
[TBL] [Abstract][Full Text] [Related]
2. Individualised treatment targets in patients with type-2 diabetes and hypertension.
Schmieder RE; Tschöpe D; Koch C; Ouarrak T; Gitt AK;
Cardiovasc Diabetol; 2018 Jan; 17(1):18. PubMed ID: 29357854
[TBL] [Abstract][Full Text] [Related]
3. Seasonal Variations in the Achievement of Guideline Targets for HbA
Sakamoto M; Matsutani D; Minato S; Tsujimoto Y; Kayama Y; Takeda N; Ichikawa S; Horiuchi R; Utsunomiya K; Nishikawa M
Diabetes Care; 2019 May; 42(5):816-823. PubMed ID: 30739885
[TBL] [Abstract][Full Text] [Related]
4. High Quality of Diabetes Care Based Upon Individualised Treatment Goals - A Cross Sectional Study in 4784 Patients in Germany.
Kloos C; Müller N; Hartmann P; Lehmann T; Sämann A; Roth J; Wolf G; Müller UA
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):294-9. PubMed ID: 26824283
[TBL] [Abstract][Full Text] [Related]
5. Achievement of treatment goals among adults with diabetes in Colombia, 2015-2019: Results from a national registry.
Mendivil CO; Amaya-Montoya M; Hernández-Vargas JA; Ramírez-García N; Romero-Díaz C; Pérez-Londoño A; Guatibonza-García V; Acuña-Merchán L
Diabetes Res Clin Pract; 2022 Apr; 186():109823. PubMed ID: 35271878
[TBL] [Abstract][Full Text] [Related]
6. A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study.
Sonmez A; Tasci I; Demirci I; Haymana C; Barcin C; Aydin H; Cetinkalp S; Ozturk FY; Gul K; Sabuncu T; Satman I; Bayram F;
Diabetes Ther; 2020 May; 11(5):1045-1059. PubMed ID: 32088879
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk factors control in Polish patients with type 2 diabetes within the first two years of diagnosis: results of the ARETAEUS1 study.
Bała MM; Leśniak W; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jaeschke R; Sieradzki J; Grzeszczak W; Banasiak W;
Kardiol Pol; 2011; 69(12):1249-57. PubMed ID: 22219100
[TBL] [Abstract][Full Text] [Related]
8. Difficulties in reaching therapeutic goals for hypertension and dysplipidaemia in patients with type 2 diabetes in general practice.
Knudsen ST; Mosbech TH; Hansen B; Kønig E; Johnsen PC; Kamper AL
Dan Med J; 2013 Dec; 60(12):A4740. PubMed ID: 24355449
[TBL] [Abstract][Full Text] [Related]
9. Achievement of cardiovascular risk factor targets according to sex and previous history of cardiovascular disease in type 2 diabetes: A population-based study.
Galbete A; Cambra K; Forga L; Baquedano FJ; Aizpuru F; Lecea O; Librero J; Ibáñez B
J Diabetes Complications; 2019 Dec; 33(12):107445. PubMed ID: 31668588
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
[TBL] [Abstract][Full Text] [Related]
11. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?
Saposnik G; Goodman SG; Leiter LA; Yan RT; Fitchett DH; Bayer NH; Casanova A; Langer A; Yan AT; ; ;
Stroke; 2009 Apr; 40(4):1417-24. PubMed ID: 19213947
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
Kereiakes DJ; Neutel J
Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies.
Montvida O; Cai X; Paul SK
Diabetes Care; 2019 Apr; 42(4):644-650. PubMed ID: 30679305
[TBL] [Abstract][Full Text] [Related]
14. Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain.
Miñambres I; Mediavilla JJ; Sarroca J; Pérez A
BMC Endocr Disord; 2016 Feb; 16():10. PubMed ID: 26887662
[TBL] [Abstract][Full Text] [Related]
15. Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes.
Vepsäläinen T; Laakso M; Kantola I; Lehto S; Juutilainen A; Rönnemaa T
J Intern Med; 2012 Dec; 272(6):611-9. PubMed ID: 22891848
[TBL] [Abstract][Full Text] [Related]
16. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study.
Akram J; Sheikh UE; Mahmood M; Donnelly R
Curr Med Res Opin; 2007 Dec; 23(12):2929-36. PubMed ID: 17931463
[TBL] [Abstract][Full Text] [Related]
18. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes.
Ayala DE; Moyá A; Crespo JJ; Castiñeira C; Domínguez-Sardiña M; Gomara S; Sineiro E; Mojón A; Fontao MJ; Hermida RC;
Chronobiol Int; 2013 Mar; 30(1-2):99-115. PubMed ID: 23098178
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
Bangalore S; Kumar S; Lobach I; Messerli FH
Circulation; 2011 Jun; 123(24):2799-810, 9 p following 810. PubMed ID: 21632497
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
Lewin AJ; Weir MR
Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
